CSPC Pharmaceutical (1093) said net profit grew by 25.1 percent year-on-year to 3.52 billion yuan (HK$4.16 billion) for the first three quarters. As of end-September, the revenue was up by 14.6 percent to 19.22 billion yuan. Finished drugs income was up 17.4 percent year-on-year to 15.71 billion yuan. Revenue from bulk vitamin C fell by 9.9 percent to 1.44 billion yuan. In the three years ahead, the group is expected to launch more than 50 new products, over 15 of which will be key products with a market potential exceeding 1 billion yuan each.

Source: The Standard November 23, 2020 06:00 UTC